CK2B is a Prognostic Biomarker and a Potential Drug Target for Hepatocellular Carcinoma.

Huiru Dai,Minling Liu, Yuxi Pan,Tingwei Li,Yihang Pan,Zhesheng Chen,Jing Li,Yuchen Liu,Shuo Fang

Recent patents on anti-cancer drug discovery（2023）

引用 0|浏览6

暂无评分

摘要

CK2B is a biomarker for HCC prognosis and could be a potential new drug target. Moreover, the association between infiltrating immune cells and CK2B in the HCC tumor microenvironment might provide a solid basis for further investigation and a potent strategy for immunotherapy of HCC.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要